ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination.

Autor: Gen S; Department of Nephrology, Saitama Sekishinkai Hospital, Sayama, Japan., Iwai T; Department of Nephrology, Saitama Sekishinkai Hospital, Sayama, Japan., Ohnari S; Department of Nephrology, Saitama Sekishinkai Hospital, Sayama, Japan., Nobe K; Department of Nephrology, Saitama Sekishinkai Hospital, Sayama, Japan., Ikeda N; Department of Nephrology, Saitama Sekishinkai Hospital, Sayama, Japan.
Jazyk: angličtina
Zdroj: Case reports in nephrology [Case Rep Nephrol] 2023 Apr 17; Vol. 2023, pp. 4906876. Date of Electronic Publication: 2023 Apr 17 (Print Publication: 2023).
DOI: 10.1155/2023/4906876
Abstrakt: We experienced a case of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis after Moderna COVID-19 vaccination. An 82-year-old woman developed pyrexia and general malaise one month after her third booster vaccine, and the symptoms persisted. Blood testing revealed inflammation, a high level of MPO-ANCA, and microscopic hematuria. MPO-ANCA-associated vasculitis was diagnosed by renal biopsy. The symptoms improved with steroid therapy. Common adverse reactions to mRNA vaccines against COVID-19 include pyrexia and general malaise, but MPO-ANCA-associated vasculitis can also occur. If pyrexia, prolonged general malaise, urinary occult blood, or renal impairment is observed, the onset of MPO-ANCA-associated vasculitis should be considered.
Competing Interests: The authors declare that there are no conflicts of interest.
(Copyright © 2023 Shiko Gen et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje